Table 3 Consumption of antianemics, hemostatics, and analgesics in patients co-morbid with iron-deficiency anemia, hypermenorrhea, and dysmenorrhea
CM nonusers | CM users | Linear regression model | ||
|---|---|---|---|---|
days/year | days/year | β (SE)a | P-value | |
Total, N b | 32710 | 11412 | ||
Antianemicsc | 7.7 ± 39.3 | 4.9 ± 23.4 | -3.50 (0.38) | < 0.0001 |
Hemostatics | 4.1 ± 24.1 | 2.6 ± 12.2 | -1.89 (0.24) | < 0.0001 |
Analgesics | 38.0 ± 62.5 | 38.0 ± 50.3 | -0.42 (0.64) | 0.5145 |
hormone-related agents | 16.4 ± 57.3 | 13.9 ± 39.7 | -3.13 (0.58) | < 0.0001 |
Iron-deficient anemia, n b | 5259 | 2213 | ||
Antianemics | 30.9 ± 73.5 | 19.1 ± 43.4 | -11.29 (1.68) | < 0.0001 |
Hemostatics | 8.3 ± 34.6 | 5.2 ± 19.3 | -3.36 (0.79) | < 0.0001 |
Analgesics | 44.8 ± 70.2 | 42.8 ± 57.4 | -2.24 (1.69) | 0.1849 |
hormone-related agents | 14.2 ± 40.6 | 14.0 ± 31.5 | -1.20 (1.27) | 0.34 |
Hypermenorrhea, n | 8388 | 3650 | ||
Antianemics | 13.2 ± 49.6 | 8.5 ± 28.8 | -5.17 (0.85) | < 0.0001 |
Hemostatics | 7.9 ± 34.2 | 4.0 ± 13.5 | -4.01 (0.59) | < 0.0001 |
Analgesics | 41.7 ± 63.3 | 38.9 ± 47.4 | -3.51 (1.16) | 0.0026 |
hormone-related agents | 24.0 ± 71.1 | 16.1 ± 39.0 | -7.84 (1.26) | <0.0001 |
Dysmenorrhea, n | 7456 | 4246 | ||
Antianemics | 7.9 ± 37.4 | 5.7 ± 24.1 | -2.81 (0.62) | < 0.0001 |
Hemostatics | 4.8 ± 24.8 | 2.8 ± 11.8 | -2.13 (0.40) | < 0.0001 |
Analgesics | 41.0 ± 61.8 | 37.2 ± 47.0 | -3.46 (1.07) | 0.0013 |
hormone-related agents | 17.1 ± 56.2 | 12.5 ± 33.1 | -4.96 (0.94) | <0.0001 |